

Annual Report for

Oxcia AB

556932-4717

The financial year
2014-01-01 - 2014-12-31

Table of contents:

Page

Directors' Report	1
Income Statement	2
Balance Sheet	3-4
Pledged assets and contingent liabilities	4
Notes	5-6
Signatures	7

Directors' Report

The Board of Directors and the managing director of Oxcia AB, 556932-4717, hereby submit the Annual Report 2014, for the company 2nd financial year.

Company overview

Oxcia AB, with place of business at Solna, conducts research and development in biotechnology and pharmaceutical chemistry and operates within the Karolinska Institutet Science Park in Solna.

Important events 2014

The company started active operations in the fall of 2014. As a first step it broadened the number of shareholders so that by the turn of 2014/2015 it had more than 70 shareholders. The owners are distributed both within and outside Sweden.

In November, the company made an agreement with Thomas Helledays Foundation for Medical Research. ("Foundation"). Through the agreement, the company undertook at its own expense to develop and commercialize the MTH1 inhibitors project (the "Project") on behalf of the Foundation. The Project is aimed to develop treatment of cancer through so-called MTH1 inhibitors. The commitment also includes to stand the cost of patents relating to all patents that the foundation owns or may own and also the cost for administering the Foundation's daily activities. In consideration for its commitment, the company earns part of the foundation's income from the Project.

Important events in 2015

In 2015, the company took up a short-term loan to finance its operations and particularly the costs incurred in connection with the agreement with the Foundation.

During 2014 and presently, the company actively manages negotiations with global pharmaceutical companies about licensing rights to the Project. Negotiations are expected to continue unabated. The company has in its activities during 2014 and 2015 focused its activities on carrying out its undertakings in relation to the Foundation.

Overview of company's operations, result and finances SEK

	2014-12-31	2013-12-31
Total assets	690 886	50 084
Return on Equity %	-50.4	N/A
Equity ratio %	9,6	99,6

The company is in a start-up phase and has had no operations before 2013.

Proposed allocation of company profit or loss

The Board of Directors proposes that the accumulated loss of SEK 33 461, is accommodated as follows:

	<i>Amounts in SEK</i>
Carried forward	67
Profit for the year	-33 528
Total	-33 461

Regarding the results and position in general, reference is made to the subsequent results and balance sheet with the associated notes

Income Statement

<i>Amounts in SEK</i>	<i>Note</i>	<i>2014-01-01- 2014-12-31</i>	<i>2013-05-21- 2013-12-31</i>
Net sales		-	-
<i>Operating expenses</i>			
Other external costs		-33 548	-
Operating profit		-33 548	-
<i>Profit from financial items</i>			
Other interest income and similar income		20	84
Profit after financial items		-33 528	84
Profit before tax		-33 528	84
Tax on profit for the year	5	-	-17
Net profit for the year		-33 528	67

Balance Sheet

<i>Amounts in SEK</i>	<i>Note</i>	<i>2014-12-31</i>	<i>2013-12-31</i>
ASSETS			
Fixed assets			
<i>Intangible assets</i>			
Capitalized expenditure for development and similar	3	416 261	-
		416 261	-
Total fixed assets		416 261	-
Current assets			
<i>Current receivables</i>			
Other receivables		201 142	-
		201 142	-
<i>Cash and bank balances</i>		73 483	50 084
Total current assets		274 625	50 084
TOTAL ASSETS		690 886	50 084

Balance Sheet

<i>Amounts in SEK</i>	<i>Note</i>	<i>2014-12-31</i>	<i>2013-12-31</i>
EQUITY AND LIABILITIES			
Equity	4		
<i>Restricted equity</i>			
Share capital (1 000 000 shares)		100 000	50 000
		100 000	50 000
<i>Non-restricted equity</i>			
Profit or loss brought forward		67	-
Profit for the year		-33 528	67
		-33 461	67
Total equity		66 539	50 067
Current liabilities			
Accounts payable - trade		6 951	-
Tax liability		-	17
Accrued expenses and deferred income		617 396	-
		624 347	17
TOTAL EQUITY AND LIABILITIES		690 886	50 084

Pledged assets and contingent liabilities

Securities pledged

	<i>2014-12-31</i>	<i>2013-12-31</i>
<i>Pledges and securities</i>	<i>None</i>	<i>None</i>
<i>Other pledged assets and collateral</i>	<i>None</i>	<i>None</i>
Contingent liabilities		
<i>Contingent liabilities</i>	<i>None</i>	<i>None</i>

Notes

Note 1 Accounting principles

Amounts in SEK unless otherwise stated

General accounting principles

The annual report has been prepared in accordance with the Annual Accounts Act and the Accounting Standards Board's general guidelines BFNAR 2012:1 Annual and Group Reports (K3).

First-time Adoption of BFNAR 2012: 1 (K3)

This is the first time the company applies BFNAR 2012: 1 Annual report and consolidated. Transition to K3 has not affected the company's income statement and balance sheet and notes apart from increased disclosure requirements. No effects have therefore affected the company's equity at the time of transition or the comparison year. The transition has not led to any company significant accounting policies have been changed.

Valuation principles etc

Assets, provisions and liabilities are valued based on cost unless otherwise stated.

Judgments and estimates

Preparation of financial statements and application of accounting policies, are often based on management judgments, estimates and assumptions deemed to be reasonable at the time the assessment is made. Estimates and assumptions are based on historical experience and several other factors, which under prevailing circumstances are considered reasonable. The result of these are used to assess the carrying amounts of assets and liabilities that are not otherwise evident from other sources. The actual outcome may differ from these estimates.

Translation of items in foreign currency

Receivables and payables in foreign currencies are valued at the closing rate. Exchange gains and losses on operating receivables and liabilities are reported in operating result while exchange gains and losses on financial receivables and liabilities are reported as financial items.

Revenue Recognition

Revenue is recognized at the fair value of the company has received or will receive. This means that the company recognizes revenue at nominal value (invoice amount) if the company receives compensation in cash directly at the delivery. Deductions are made for discounts.

The sale of goods is normally recognized as revenue when the significant risks and rewards associated with ownership of the goods have been transferred from the company to the buyer

Note 2 Employees and personnel costs

The company did not have any employees during the financial year. Remuneration to the Board of Directors was not paid.

Note 3 Capitalised expenditure for development work and similar

	2014-12-31	2013-12-31
<i>Accumulated cost of acquisitions</i>		
-Miscellaneous investments	416 261	-
At the end of the year	416 261	-
<i>Accumulated depreciation</i>		
-Depreciation for the year	-	-
At the end of the year	-	-
Carrying amount at year-end	416 261	-

The item relates to costs incurred in connection with the development and commercialization of rights in connection with the MTH1 project and has been reduced by a public contribution from Vinnova of SEK 200 000.

Note 4 Equity

	<i>Share capital</i>	<i>Statutory reserve</i>	<i>Balance Sheet profit</i>	<i>Year's profit</i>
At beginning of year	50 000	-	-	67
Share issue	50 000			
Transfer of previous year's profit			67	-67
Profit for the year				-33 528
At the end of the year	100 000	-	67	-33 528

Note 5

The Company has not paid any tax during the year and report a loss before tax of 33 528 SEK. There are no significant fiscal adjustments items and therefore the year's cost for tax is zero.

Signatures

Solna 21 may 2015

Ulla Warpman Berglund
Chairman of the Bord

Annika Jenmalm Jensen

Annika Jenmalm Jensen

Ulla Warpman Berglund

Johannes Linde

Johannes Linde

Jan Zetterberg
Cheif Executive Officer

Jan Zetterberg

My Audit Report was submitted on 25 May 2015
Ernst & Young

Magnus Karlström
Authorized public accountant